Order Article Reprints

Garcia Campelo MR, Zhou C, Ramalingam SS, Lin HM, Kim TM, Riely GJ, Mekhail T, Nguyen D, Goodman E, Mehta M, et al. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. Journal of Clinical Medicine. 2023; 12(1):112. https://doi.org/10.3390/jcm12010112

Garcia Campelo, Maria Rosario, Caicun Zhou, Suresh S. Ramalingam, Huamao M. Lin, Tae Min Kim, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, and et al. 2023. "Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort" Journal of Clinical Medicine 12, no. 1: 112. https://doi.org/10.3390/jcm12010112

Garcia Campelo, M. R., Zhou, C., Ramalingam, S. S., Lin, H. M., Kim, T. M., Riely, G. J., Mekhail, T., Nguyen, D., Goodman, E., Mehta, M., Popat, S., & Jänne, P. A. (2023). Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. Journal of Clinical Medicine, 12(1), 112. https://doi.org/10.3390/jcm12010112